Omeros

OMER

Market cap $776M

Omeros NASDAQ: OMER reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA.

Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include: First Quarter and Recent Highlights In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million. Net income for the first quarter of.

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the first quarter 2026 on Wednesday, May 13, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please click.

Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.

The consensus price target hints at a 222.8% upside potential for Omeros (OMER). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for YARTEMLEA®. The J-code for YARTEMLEA (J1289) simplifies and streamlines billing and reimbursement for patients covered by U.S. government programs (e.g., Medicare) and commercial payers. The J-code will become effective July 1, 2026. “For patients with TA-TMA, access to e.

The average of price targets set by Wall Street analysts indicates a potential upside of 266.7% in Omeros (OMER). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Omeros Corporation maintains a Buy rating, driven by Yartemlea's FDA approval for TA-TMA and the Novo Nordisk zaltenibart deal. OMER's 2025 net loss narrowed to $(3.35m) due to a $237.6m gain on zaltenibart rights; cash position improved and debt reduced by 47%. Yartemlea, priced at $36k per vial, targets a potential $5.4bn TAM with first-mover advantage, but faces potential pricing and competitive risks as Soliris generics emerge.